Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Guidelines for the Management of Venous Thromboembolism in End-of-Life Cancer Patients: National Consensus].

Acta medica portuguesa·2026
Same author

Multi-Analyte Method for Antibiotic Residue Determination in Honey Under EU Regulation 2021/808.

Antibiotics (Basel, Switzerland)·2025
Same author

Treatment of Locally Advanced and Metastatic Salivary Gland Cancer: A 10-year Experience of an Oncology Center in Portugal.

Acta medica portuguesa·2025
Same author

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Development and Optimization of Extraction Methodologies for the Determination of Antibiotics in Honey by UHPLC-ToF-MS.

Journal of AOAC International·2025
Same author

Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.

JAMA·2025
Same journal

[Presence of Dermatologists on Social Media: Perception of the Portuguese Population].

Acta medica portuguesa·2026
Same journal

[Sexual Health in Oncology Patients and Cancer Survivors: A Structured Protocol to Address an Unmet Clinical Need at IPO-Porto].

Acta medica portuguesa·2026
Same journal

Hyperthermia in a Teenager: Is it Just a Heat Stroke?

Acta medica portuguesa·2026
Same journal

Cutaneous Polyarteritis Nodosa as the Inaugural Manifestation of Hairy Cell Leukemia.

Acta medica portuguesa·2026
Same journal

Alopecia Neoplastica from Breast Carcinoma: When Hair Loss Hides Something Else.

Acta medica portuguesa·2026
Same journal

[Burnout Among Residents: A Current Perspective].

Acta medica portuguesa·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

[Biosimilars in oncology].

Sérgio Barroso1, Jorge Coutinho, Margarida Damasceno

  • 1Hospital do Espírito Santo, Evora.

Acta Medica Portuguesa
|August 19, 2009
PubMed
Summary
This summary is machine-generated.

Biotechnology drugs have advanced medical therapy, especially in oncology and hematology. The introduction of biosimilars in Portugal, following patent expirations, prompts expert opinions on their clinical substitution of biological drugs.

More Related Videos

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Experiment Videos

Last Updated: Jun 20, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Area of Science:

  • Biopharmaceutical development and therapeutic advancements.
  • Exponential growth in biotechnology drug utilization.
  • Integration into oncology and hematology treatment strategies.

Context:

  • Biotechnology drugs are crucial in modern oncology and hematology.
  • Patent expiries of originator biologics enable biosimilar development.
  • Biosimilars recently approved for the Portuguese market.

Purpose:

  • Analyze state-of-the-art information on biotechnology drugs and biosimilars.
  • Examine current legislation governing biosimilars.
  • Gather expert opinions on substituting biological drugs with biosimilars in clinical practice.

Summary:

  • Biotechnology drugs represent significant medical advances, with rapidly increasing use, particularly in oncology and hematology.
  • The advent of biosimilars, following patent expiries of original biologic medications, is a recent development in Portugal.
  • This article synthesizes current knowledge and expert perspectives on the clinical integration and substitution of biologicals by biosimilars.

Impact:

  • Informing healthcare professionals and policymakers on biosimilar adoption.
  • Facilitating evidence-based decision-making regarding biosimilar use in Portugal.
  • Contributing to the understanding of biosimilar impact on cancer and blood disorder treatments.